ANIP · Ani Pharmaceuticals Inc · Earnings Call Transcripts & Audio
Market Cap
$1.61B
Shares
22.97M
Ani Pharmaceuticals Inc Earnings Call Transcripts
Quarterly earnings calls for Ani Pharmaceuticals Inc (ANIP), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲61%
$83.82M
−$8.60M
'22 Q3
22-11-09
▲54.7%
$94.23M
−$4.24M
'22 Q4
23-03-09
▲65.6%
$106.79M
$1.44M
'23 Q1
23-06-09
▲57.8%
$116.55M
$6.25M
'23 Q2
23-09-07
▲57.3%
$131.83M
$9.94M
'23 Q3
23-11-15
▲39.7%
$131.65M
$1.16M
'23 Q4
24-01-08
▲28.7%
$137.43M
$18.21M
'24 Q1
24-04-17
▲18.4%
$138.04M
−$2.29M
'24 Q2
24-08-06
▲12.5%
$148.33M
−$24.17M
'24 Q3
24-11-20
▲44.8%
$190.57M
−$10.28M
'24 Q4
25-02-28
▲43.4%
$197.12M
$15.68M
'25 Q1
25-05-09
▲53.1%
$211.37M
$8.55M
'25 Q2
25-08-08
▲53.6%
$227.81M
$26.62M
'25 Q3
25-11-07
▲29.6%
$247.06M
$27.49M
'25 Q4
26-02-27
▲20.5%
$237.46M
$29.49M
'26 Q1
26-05-08
LATEST
▲25.9%
$266.04M
$24.71M
'26 Q2
26-08-07
Earnings call
FY26 · Q2
2026-08-07
Ani Pharmaceuticals Inc (ANIP) Q2 2026 Earnings Call Transcript
Confident tone
2026 guidance and outlook
Illuvian and ophthalmology opportunity
Sales force expansion
Revenue
$266.04M
▲ 25.9% YoY Diluted EPS
$1.05
▲ 191.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Ani Pharmaceuticals Inc (ANIP) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-08
Ani Pharmaceuticals Inc (ANIP) Q1 2026 Earnings Call Transcript
Confident tone
Rare Disease Transformation / Cortrophin Gel
Capital Allocation / Share Repurchase / Business Development
Q1 Operational Headwinds / Insurance Re-verifications
Revenue
$237.46M
▲ 20.5% YoY Diluted EPS
$1.28
▲ 85.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-27
Ani Pharmaceuticals Inc (ANIP) Q4 2025 Earnings Call Transcript
Confident tone
Cortrophin rare disease growth
Acute gouty arthritis expansion
ILUVIEN commercial turnaround
Revenue
$247.06M*
▲ 29.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-07
Ani Pharmaceuticals Inc (ANIP) Q3 2025 Earnings Call Transcript
Confident tone
Cortrophin Gel Growth
ILUVIEN / Retina Reset
Sales Force Expansion
Revenue
$227.81M
▲ 53.6% YoY Diluted EPS
$1.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-08
Ani Pharmaceuticals Inc (ANIP) Q2 2025 Earnings Call Transcript
Confident tone
Rare Disease / Cortrophin Gel growth
NEW DAY clinical trial
Ophthalmology / revenue synergies
Revenue
$211.37M
▲ 53.1% YoY Diluted EPS
$0.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Ani Pharmaceuticals Inc (ANIP) Q1 2025 Earnings Call Transcript
Confident tone
Retina (ILUVIEN/YUTIQ) near-term challenges
Royalty buyout on ILUVIEN/YUTIQ
Cortrophin Gel growth and outlook
Revenue
$197.12M
▲ 43.4% YoY Diluted EPS
$0.69
▼ 15.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-28
Ani Pharmaceuticals Inc (ANIP) Q4 2024 Earnings Call Transcript
Confident tone
Cortrophin Gel growth
Alimera acquisition / ophthalmology franchise
Rare Disease franchise expansion
Revenue
$190.57M*
▲ 44.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-20
Ani Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Transcript
Confident tone
Alimera acquisition and integration
Cortrophin Gel growth
Rare Disease segment outlook
Revenue
$148.33M
▲ 12.5% YoY Diluted EPS
$-1.27
▼ 382.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Ani Pharmaceuticals Inc (ANIP) Q2 2024 Earnings Call Transcript
Confident tone
Rare disease / Cortrophin gel growth
Competitive landscape (ACTH category)
Alimera Sciences acquisition
Revenue
$138.04M
▲ 18.4% YoY Diluted EPS
$-0.14
▼ 148.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-17
Ani Pharmaceuticals Inc (ANIP) Q1 2024 Earnings Call Transcript
Confident tone
Cortrophin Gel commercial momentum
Rare disease business expansion and M&A
Financial guidance reiteration
Revenue
$137.43M
▲ 28.7% YoY Diluted EPS
$0.82
▲ 1266.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Ani Pharmaceuticals Inc (ANIP) Q4 2023 Earnings Call Transcript
Confident tone
Therapeutic area expansion
Cortrophin Gel franchise growth
Financial results and 2024 guidance
Revenue
$131.65M*
▲ 39.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-15
Ani Pharmaceuticals Inc (ANIP) Q3 2023 Earnings Call Transcript
Revenue
$131.83M
▲ 57.3% YoY Diluted EPS
$0.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-09-07
Ani Pharmaceuticals Inc (ANIP) Q2 2023 Earnings Call Transcript
Revenue
$116.55M
▲ 57.8% YoY Diluted EPS
$0.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-06-09
Ani Pharmaceuticals Inc (ANIP) Q1 2023 Earnings Call Transcript
Revenue
$106.79M
▲ 65.6% YoY Diluted EPS
$0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Ani Pharmaceuticals Inc (ANIP) Q4 2022 Earnings Call Transcript
Revenue
$94.23M*
▲ 54.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Ani Pharmaceuticals Inc (ANIP) Q3 2022 Earnings Call Transcript
Revenue
$83.82M
▲ 61% YoY Diluted EPS
$-0.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Ani Pharmaceuticals Inc (ANIP) Q2 2022 Earnings Call Transcript
Revenue
$73.86M
▲ 51.9% YoY Diluted EPS
$-0.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Ani Pharmaceuticals Inc (ANIP) Q1 2022 Earnings Call Transcript
Revenue
$64.48M
▲ 18.3% YoY Diluted EPS
$-1.27
▼ 12800% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-15
Ani Pharmaceuticals Inc (ANIP) Q4 2021 Earnings Call Transcript
Revenue
$60.93M*
▲ 6.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-01
Ani Pharmaceuticals Inc (ANIP) Q3 2021 Earnings Call Transcript
Revenue
$52.06M
▼ 1.7% YoY Diluted EPS
$-0.37
▼ 1025% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-06
Ani Pharmaceuticals Inc (ANIP) Q2 2021 Earnings Call Transcript
Revenue
$48.62M
▲ 0.3% YoY Diluted EPS
$-1.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-07
Ani Pharmaceuticals Inc (ANIP) Q1 2021 Earnings Call Transcript
Revenue
$54.52M
▲ 9.5% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-09
Ani Pharmaceuticals Inc (ANIP) Q4 2020 Earnings Call Transcript
Revenue
$57.25M
▲ 19.4% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Ani Pharmaceuticals Inc (ANIP) Q3 2020 Earnings Call Transcript
Revenue
$52.98M
▲ 3.2% YoY Diluted EPS
$0.04
▼ 87.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Ani Pharmaceuticals Inc (ANIP) Q2 2020 Earnings Call Transcript
Revenue
$48.47M
▼ 10.8% YoY Diluted EPS
$-1.03
▼ 294.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Ani Pharmaceuticals Inc (ANIP) Q1 2020 Earnings Call Transcript
Revenue
$49.77M
▼ 5.9% YoY Diluted EPS
$-0.59
▼ 1575% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Ani Pharmaceuticals Inc (ANIP) Q4 2019 Earnings Call
Revenue
$47.97M
▼ 16% YoY Diluted EPS
$-0.41
▼ 189.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1023024
CUSIP
00182C103
13F (30d)
195 filings
194 filers
Visit website
Investor relations